Special Issue

Drug Resistance of Head and Neck Cancer

Message from the Guest Editor

Drug resistance in head and neck cancer (HNC) remains a major health problem worldwide. HNC can arise in the lips, oral cavity, nasal cavity, pharynx, larynx, and salivary glands, and accounts for approximately 890,000 new cases and more than 450,000 deaths each year. The majority of HNC occurs in the oral cavity and approx. 90% of HNC is categorized as head and neck squamous cell carcinoma. Despite the recent advances in therapeutic modalities, the prognosis and 5-year survival rates for patients with advanced, recurrent, and metastatic diseases remain poor due to treatment resistance. The current standard-of-care for HNC involves surgical removal combined with radiation and chemotherapy or immunotherapy. Unfortunately, more than half of locally advanced HNC cases recur or become metastatic following initial treatments and are no longer responsive. Multidrug resistance and survival mechanisms driving drug efflux, metabolism, noncoding RNAs, and cancer stem cells are known to contribute to the resistance in HNC and remain to be fully explored. The current Special Issue will address the current status and future novel directions for understanding drug resistance in HNC.

Guest Editor

Dr. Ali Khammanivong

Dickerson Laboratory, Masonic Cancer Center, University of Minnesota, 420 Delaware Street SE, Minneapolis, MN 55455, USA

Deadline for manuscript submissions

closed (30 September 2021)

Biology

an Open Access Journal by MDPI

Impact Factor 3.5
CiteScore 7.4
Indexed in PubMed

mdpi.com/si/64541

Biology
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biology@mdpi.com

mdpi.com/journal/biology

Biology

an Open Access Journal by MDPI

Impact Factor 3.5
CiteScore 7.4
Indexed in PubMed

mdpi.com/journal/biology

About the Journal

Message from the Editorial Board

A major strength of biological science is the diversity of approaches that biological scientists apply to their research problems. *Biology* reflects this diversity and brings together studies employing the varied experimental and theoretical approaches that are fueling biological discovery. *Biology*, the journal, is a fully peer-reviewed publication with a rapid and economical route to open access publication and is listed on PubMed. All articles are peer-reviewed and the editorial focus is on determining that the work is scientifically sound rather than trying to predict its future impact.

Editors-in-Chief

Prof. Dr. Jukka Finne
Research Programme in Molecular and Integrative Biosciences, Faculty of Biological and Environmental Sciences, University of Helsinki, P.O. Box 56, FI-00014 Helsinki, Finland

Prof. Dr. Andrés Moya
Integrative Systems Biology Institute, University of Valencia and CSIC, 46980 Valencia, Spain

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, PubAg, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Biology) / CiteScore - Q1 (General Agricultural and Biological Sciences)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17.4 days after submission; acceptance to publication is undertaken in 2.5 days (median values for papers published in this journal in the first half of 2025).

MDPI